SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC

This is a multicenter, cohort, prospective study to evaluate the efficacy and safety of Adebrelimab combined with radiotherapy and chemotherapy as preoperative neoadjuvant therapy for patients with locally advanced rectal cancer. In the study, all subjects who meet the inclusion criteria will enter the short-term radiotherapy queue and the long-term radiotherapy queue at the ratio of 1:1. The short-term radiotherapy queue plans to receive Adebrelimab combined with short-term radiotherapy (5\*5Gy) and Capox chemotherapy as neoadjuvant therapy. The long-term radiotherapy queue plans to receive A

Trial Details

NCT ID
NCT07284992
Phase
PHASE2
Sponsor
Shandong Provincial Hospital
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • short-term radiotherapy combined with Adebrelimab and capox
  • long-term radiotherapy combined with Adebrelimab and capox
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • 1\. sign written informed consent before implementing any test related process;
  • 2\. Patients diagnosed as rectal adenocarcinoma by primary biopsy and histopathological examination;
  • 3\. patients with CT stage ≥ T3 or CN stage N1+, M0 or EMVI (+) or MRF (+) or suspected lateral lymph node metastasis (\>5mm) who are judged by ima…
  • 4\. according to imaging and colonoscopy, the main body of the tumor was located ≤ 10cm from the anal edge;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →